Car T-Cell Therapy

The Institute for Clinical and Economic Review published a draft evidence report assessing the comparative clinical effectiveness and value of B-cell maturation antigen-directed therapies for heavily pretreated multiple myeloma.

The FDA cleared an investigational new drug application for KITE-222, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory acute myeloid leukemia, according to the agent’s manufacturer.

The uptake of chimeric antigen receptor T-cell therapy has been sluggish despite its tantalizing promise to provide a cure for a large proportion of patients with advanced large B-cell lymphoma.

The FDA granted accelerated approval to lisocabtagene maraleucel for adults with relapsed or refractory large B-cell lymphoma who received at least two prior therapies.

Although colorectal cancer mortality has declined steadily since the 1940s, the long-term prognosis for patients with late-stage metastatic disease has remained relatively poor.

Challenges presented by the COVID-19 pandemic did not stop progress in research or clinical development of gene and cell therapies, according to a state-of-the-industry briefing by Alliance of Regenerative Medicine.

The FDA lifted its clinical hold on a study evaluating BPX-601 and rimiducid for patients with previously treated metastatic pancreatic or prostate cancers, according to a press release from the agent’s manufacturer.

Little is known about the long-term issues facing cancer survivors who received chimeric antigen receptor T-cell therapy, primarily because the therapy is relatively new.

An allogeneic chimeric antigen T-cell therapy showed evidence of clinical activity among patients with metastatic colorectal cancer, according to results of a dose-escalation study presented at Gastrointestinal Cancers Symposium.

Jakub Svoboda, MD, of Penn Medicine, discussed data from the ZUMA-12 study presented at the ASH Annual Meeting and Exposition.